Janssen Biotech $JNJ submitted Biologics License Application (BLA) to the FDA seeking approval of treatment, sirukumab, intended for adult patients having moderate to severely active rheumatoid arthritis (RA), a chronic systemic inflammatory condition affecting nearly 1.5 million Americans.